Cullen/Frost Bankers’s Guardant Health GH Stock Holding History

Cullen/Frost Bankers’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$204	–	1458
2025 Q4	$204	Buy	+2	New	+$179	﹤0.01%	1399
2020 Q4	–	Sell	-4	Closed	–	–	1102
2020 Q3	$0	Buy	+4	New	+$366	﹤0.01%	1193

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cullen/Frost Bankers's GH Position: Q1 2026 in Review

Cullen/Frost Bankers sold out of Guardant Health (GH) in Q1 2026, closing a stake of 2 shares — an estimated $204 sold.

Cullen/Frost Bankers first reported a position in GH in Q3 2020 and held it in 2 quarters. The position peaked at $204 in Q4 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Cullen/Frost Bankers reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
Cullen/Frost Bankers sold 2 Guardant Health shares in Q1 2026, an estimated $204.
Cullen/Frost Bankers first reported a position in Guardant Health in Q3 2020 and held it in 2 quarters.
Cullen/Frost Bankers's Guardant Health position peaked at $204 in Q4 2025.
481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.